Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Apr 1;2(4):641-645.
doi: 10.1016/j.jaccas.2019.12.038. eCollection 2020 Apr.

Osimertinib-Induced Cardiomyopathy

Shruti R Patel  1 , Sherry-Ann N Brown  2 , Jilan E Kubusek  3 , Aaron S Mansfield  3 , Narjust Duma  4
Affiliations
Case Reports

Osimertinib-Induced Cardiomyopathy

Shruti R Patel et al. JACC Case Rep. .

Abstract

Osimertinib is the preferred treatment in patients with metastatic non-small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.).

Keywords: CHF, congestive heart failure; EF, ejection fraction; EGFR, epidermal growth factor receptor; NSCLC, non–small cell lung cancer; TKI, tyrosine kinase inhibitor; cardio-oncology; cardiotoxicity; heart failure; osimertinib; reduced ejection fraction.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1
Figure 1
Computed Tomography of the Chest Demonstrating Pulmonary Sequela of Heart Failure (A) Prior to dose escalation from 40 to 80 mg osimertinib. (B) Pulmonary edema (arrow) and bilateral effusions (star) 4 weeks after osimertinib dose escalation.
See this image and copyright information in PMC

References

    1. Soria J.-C., Ohe Y., Vansteenkiste J. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125. - PubMed
    1. Anand K., Ensor J., Trachtenberg B., Bernicker E. Osimertinib induced cardio-toxicity: a retrospective review of FDA adverse events reporting system (FAERS) J Clin Oncol. 2019;37:9044. - PMC - PubMed
    1. Scott L.J. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drugs Ther Perspect. 2018;34:351–357. - PMC - PubMed
    1. Goss G., Tsai C.M., Shepherd F.A. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17:1643–1652. - PubMed
    1. U.S. Food and Drug Administration Center for Drug Evaluation and Research. TAGRISSO (osimertinib) tablets, for oral use. http://www.fda.gov/medwatch Available at:

Publication types